BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SCOLR Pharma, Inc. (DDD) Announces Issuance of European Patent for CDT® Ibuprofen


7/11/2012 10:28:36 AM

BELLEVUE, Wash., July 11, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (PINK: SCLR) today announced that the European Patent Office has issued a patent covering SCOLR's oral modified release ibuprofen formulation, which is based on SCOLR's CDT® Controlled Delivery Technology platform.

European patent number 1,793,809 covers SCOLR's approach for optimizing the release profile of ibuprofen, in order to achieve particular blood level concentrations of this active ingredient for a therapeutic purpose.

Stephen Turner, President and CEO of SCOLR, said: "The grant of this patent expands our ibuprofen-related intellectual property portfolio while providing potential value to this product for our future partners. Although our business and available resources are focused on growing our nutritional products business into a sustainable source of revenue, we believe that this patent enhances the global market opportunity for our 12-hour ibuprofen formulation and we intend to continue to seek appropriate partnership opportunities for the commercialization of the product."

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call (425) 368-1050 or visit http://www.scolr.com/.

Forward looking statements:

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements regarding growth of SCOLR's nutritional business, market opportunities related to SCOLR's ibuprofen product, potential partnership opportunities and potential commercialization of SCOLR's ibuprofen product. Factors that could cause these forward-looking statements to differ from actual results include adverse consumer or retailer reception of SCOLR's products, unfavorable regulatory determinations, competitive factors and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:

Investor Relations:

SCOLR Pharma, Inc.

425.368.1050

SOURCE SCOLR Pharma, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES